GlassScriptPhysician profile
Laura M Anderson
NPI 1629726369
$3,680.53
in general payments reported to CMS, 2019-2025
23 companies · $1,762 in 2025
The $1,762 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $323 · 2023: $835 · 2024: $761 · 2025: $1,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,303 · Education: $54.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,303.37 |
| Education | $54.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $918.62 | 2022-2025 | Watchman Flx, Farapulse |
| Medtronic, INC. | $341.88 | 2022-2023 | Micra |
| Biosense Webster, INC. | $291.61 | 2025 | Carto 3 |
| Edwards Lifesciences Corporation | $260.59 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Averitas Pharma INC. | $223.53 | 2023-2025 | Qutenza |
| Novartis Pharmaceuticals Corporation | $177.69 | 2025 | |
| Amgen INC. | $156.38 | 2024-2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $151.63 | 2024-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $138.51 | 2023-2025 | Fasenra, Farxiga |
| Neurocrine Biosciences, INC. | $126.33 | 2024 | Ingrezza |
| Exeltis, USA INC. | $123.98 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $122.49 | 2024 | Austedo Xr |
| Glaxosmithkline, LLC. | $121.86 | 2025 | Arexvy |
| Sanofi-Aventis U.S. LLC | $121.47 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $109.31 | 2025 | Camzyos |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.30 | 2023-2024 | Jardiance |
| Coloplast Corp | $62.68 | 2023 | Titan |
| Pfizer INC. | $46.05 | 2025 | |
| Impulse Dynamics (USA) INC. | $32.14 | 2025 | Optimizer |
| Lexicon Pharmaceuticals, INC. | $20.49 | 2023 | Inpefa |
| Resmed Corp | $19.73 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.61 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $15.65 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.